Back to results
RecruitingPhase 3

NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

NCT06911112

What is this trial?

Generating plain-language summary...

Am I eligible?

Generating eligibility summary...

What's involved?

Summarizing study design...

Where and how to apply

Primary location

Neurocrine Clinical Site

Huntsville, Alabama, United States

+9 additional locations

Contact

Neurocrine Medical Information Call Center

1-877-641-3461medinfo@neurocrine.com
View on ClinicalTrials.gov
NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) — TrialFind